Fresenius Kabi Deutschland Gmbh Pharmaceutical Import Profile — Germany (DGFT 2022–2026)

Name: Fresenius Kabi Deutschland Gmbh Pharmaceutical Import Records from India — 10 Products, $65.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fresenius Kabi Deutschland Gmbh — Pharmaceutical Importer Profile (2026) | 10 Products, $65.5M Trade | TransData Nexus

Fresenius Kabi Deutschland Gmbh

Pharmaceutical Importer · Germany · Oncology Focus · $65.5M Total Trade · DGFT Verified

Fresenius Kabi Deutschland Gmbh is a pharmaceutical importer based in Germany with a total trade value of $65.5M across 10 products in 2 therapeutic categories. Based on 2,363 verified import shipments from Indian Customs (DGFT) records, Fresenius Kabi Deutschland Gmbh is the #1 buyer in 5 products including Paclitaxel, Carboplatin, Oxaliplatin. Fresenius Kabi Deutschland Gmbh sources from 2 verified Indian suppliers, with Fresenius Kabi Oncology Limited accounting for 100.0% of imports.

Fresenius Kabi Deutschland Gmbh — Import Portfolio & Supplier Network

Fresenius Kabi Deutschland Gmbh import network — 10 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Fresenius Kabi Deutschland Gmbh?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Fresenius Kabi Oncology Limited	$57.2M	2,659	100.0%
Fresenius Kabi India Private Limited	$25	2	0.0%

Fresenius Kabi Deutschland Gmbh sources from 2 verified Indian suppliers across 1,901 distinct formulations.

What Formulations Does Fresenius Kabi Deutschland Gmbh Import?

Formulation	Value	Ships
Paclitaxel kabi INJ.300MG/50ML vial	$1.2M	33
Paclitaxel fresenius kabi INJ.300MG/50ML	$638.9K	17
Oxaliplatin kabi INJ.200MG/40ML vial	$607.6K	15
Pemetrexed fresenius kabi INJ.500MG/20ML	$560.5K	30
Irinotecan kabi INJ.500MG/25ML vial	$488.4K	18
Pemetrexed fresenius kabi INJ.	$486.9K	16
Pemetrexed fresenius kabi	$483.5K	14
Paclitaxel fresenius kabi	$360.9K	17
Pemetrexed fresenius kabi INJ.	$360.9K	15
Carboplatin fresenius kabi INJ.	$316.5K	8
Paclitaxel kabi INJ. 300MG/50ML vial	$316.4K	7
Carboplatin fresenius kabi	$302.0K	8
Paclitaxel fresenius kabi INJ.150MG/25ML	$291.6K	11
Oxaliplatin kabi INJ.200MG/40ML	$286.2K	11
Paclitaxel kabi INJ.100MG/16.7ML vial b.	$270.4K	14

Fresenius Kabi Deutschland Gmbh imports 1,901 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 10 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Paclitaxel	Oncology	$17.2M	513	20.6%	1
2	Carboplatin	Oncology	$15.9M	391	22.4%	1
3	Oxaliplatin	Advanced Oncology	$10.0M	362	21.5%	1
4	Pemetrexed	Advanced Oncology	$8.7M	289	30.1%	1
5	Irinotecan	Oncology	$8.1M	452	19.6%	1
6	Docetaxel	Oncology	$2.5M	144	6.4%	3
7	Gemcitabine	Oncology	$1.6M	64	3.4%	5
8	Bortezomib	Advanced Oncology	$609.5K	66	2.8%	7
9	Etoposide	Oncology	$475.0K	22	4.4%	3
10	Busulfan	Advanced Oncology	$426.4K	60	8.7%	3

Fresenius Kabi Deutschland Gmbh imports 10 pharmaceutical products across 2 categories into Germany totaling $65.5M. The company is the #1 buyer for 5 products: Paclitaxel, Carboplatin, Oxaliplatin, Pemetrexed, Irinotecan.

Fresenius Kabi Deutschland Gmbh — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Fresenius Kabi Deutschland GmbH, headquartered in Bad Homburg, Germany, is a subsidiary of the global healthcare company Fresenius SE & Co. KGaA. Established in 1999, Fresenius Kabi specializes in the development, production, and distribution of essential medicines and technologies for infusion, transfusion, and clinical nutrition. The company's product portfolio includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and intravenous generic drugs. Fresenius Kabi employs over 40,000 people worldwide and reported sales exceeding €8 billion in 2024.

2Distribution Network

Fresenius Kabi Deutschland GmbH operates a comprehensive distribution network within Germany and internationally. While specific warehouse locations are not publicly disclosed, the company maintains a global presence with production sites in Europe, North America, Latin America, Asia Pacific, and Africa. This extensive infrastructure ensures efficient logistics capabilities and broad geographic coverage, facilitating the timely delivery of products to healthcare providers and patients.

3Industry Role

In Germany's pharmaceutical supply chain, Fresenius Kabi Deutschland GmbH functions primarily as a wholesaler and distributor. The company imports a diverse range of pharmaceutical formulations, including oncology drugs, from various international suppliers, including India. By sourcing and distributing these products, Fresenius Kabi plays a crucial role in ensuring the availability of essential medications to healthcare facilities and patients across Germany.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Fresenius Kabi Deutschland Gmbh

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Fresenius Kabi Deutschland GmbH's sourcing strategy exhibits a high degree of concentration, particularly in its imports from India. The company has imported finished pharmaceutical formulations totaling $65.5 million from India, comprising 2,363 shipments across 10 products in two therapeutic categories. Notably, the top five products—Paclitaxel, Carboplatin, Oxaliplatin, Pemetrexed, and Irinotecan—account for 91.4% of the total import value. This concentration indicates a strategic focus on specific oncology treatments, which may offer cost advantages and supply chain efficiencies. However, such dependency on a limited number of products and suppliers could pose risks related to supply disruptions or regulatory changes affecting these specific drugs.

2Supply Chain Resilience

The resilience of Fresenius Kabi Deutschland GmbH's Indian supply chain is influenced by its reliance on a limited number of suppliers and products. With 100% of its Indian imports sourced from Fresenius Kabi Oncology Limited, the company faces potential vulnerabilities if this supplier encounters operational challenges or regulatory issues. The high concentration in specific formulations, such as Paclitaxel and Carboplatin, further amplifies this risk. To enhance supply chain resilience, it would be prudent for Fresenius Kabi to diversify its supplier base and product portfolio, thereby mitigating potential disruptions.

Importing Pharmaceuticals into Germany — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Germany

1Regulatory Authority & Framework

In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing pharma imports includes the German Medicines Act (AMG), which outlines requirements for marketing authorization, quality control, and distribution. For Indian generics to be marketed in Germany, they must undergo a centralized marketing authorization procedure through the European Medicines Agency (EMA), ensuring compliance with EU standards for safety, efficacy, and quality.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Germany stipulate that all imported drugs must possess a valid marketing authorization from the EMA. Additionally, Good Manufacturing Practice (GMP) certificates from recognized authorities, such as the EU GMP, WHO GMP, or PIC/S, are mandatory to ensure product quality and safety. Wholesale distribution authorization is also required, which involves compliance with specific storage, handling, and distribution standards to maintain the integrity of pharmaceutical products throughout the supply chain.

3Quality & Labeling

Fresenius Kabi Deutschland Gmbh — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Fresenius Kabi Deutschland GmbH's focus on importing oncology drugs, particularly Paclitaxel, Carboplatin, Oxaliplatin, Pemetrexed, and Irinotecan, aligns with the growing demand for cancer treatments in Germany. The high import values and market shares of these products indicate a strategic emphasis on providing essential medications for oncology patients. This focus is driven by the increasing prevalence of cancer and the need for effective therapies, positioning Fresenius Kabi as a key supplier in this therapeutic area.

2Sourcing Profile

Fresenius Kabi Deutschland GmbH's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from select suppliers, with a significant portion sourced from India. The company's preference for specific formulations, such as those used in oncology, reflects a targeted approach to meet market demand. India's established pharmaceutical manufacturing capabilities and cost advantages make it a strategic partner for Fresenius Kabi in sourcing these products.

3Market Positioning

Based on its product mix, Fresenius Kabi Deutschland GmbH serves multiple segments of the German pharmaceutical market, including hospital supply, wholesale distribution, and potentially government tenders. The company's focus on oncology drugs positions it as a critical supplier to healthcare providers treating cancer patients, ensuring the availability of essential medications in various healthcare settings.

Seller's Guide — How to Become a Supplier to Fresenius Kabi Deutschland Gmbh

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Fresenius Kabi Deutschland GmbH, particularly in the oncology drug segment. By offering high-quality products that meet EU regulatory standards and ensuring reliable supply chains, Indian exporters can fill gaps in Fresenius Kabi's current sourcing, especially for products not currently imported from India. This collaboration can enhance product diversity and supply chain resilience for Fresenius Kabi.

2Requirements & Qualifications

Indian exporters aiming to supply Fresenius Kabi Deutschland GmbH must obtain marketing authorization from the EMA for their products. They must also possess GMP certifications from recognized authorities, such as the EU GMP, WHO GMP, or PIC/S. Additionally, compliance with German labeling requirements, including German language labeling and serialization mandates, is essential. Establishing a wholesale distribution authorization in Germany is also necessary to ensure adherence to local distribution standards.

3How to Approach

Frequently Asked Questions — Fresenius Kabi Deutschland Gmbh

What products does Fresenius Kabi Deutschland Gmbh import from India?

Fresenius Kabi Deutschland Gmbh imports 10 pharmaceutical products across 2 categories. Top imports: Paclitaxel ($17.2M), Carboplatin ($15.9M), Oxaliplatin ($10.0M), Pemetrexed ($8.7M), Irinotecan ($8.1M).

Who supplies pharmaceuticals to Fresenius Kabi Deutschland Gmbh from India?

Fresenius Kabi Deutschland Gmbh sources from 2 verified Indian suppliers. The primary supplier is Fresenius Kabi Oncology Limited (100.0% of imports, $57.2M).

What is Fresenius Kabi Deutschland Gmbh's total pharmaceutical import value?

Fresenius Kabi Deutschland Gmbh's total pharmaceutical import value from India is $65.5M, based on 2,363 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Fresenius Kabi Deutschland Gmbh focus on?

Fresenius Kabi Deutschland Gmbh imports across 2 categories. The largest: Oncology (69.8%), Advanced Oncology (30.2%).

Get Full Fresenius Kabi Deutschland Gmbh Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.